Nektar Therapeutics (NKTR) PT Raised to $63 at Evercore ISI; 'Highlights from 4Q earnings call'
Evercore ISI raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $63.00 (from $31.00) while maintaining a In Line rating.
Evercore ISI raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $63.00 (from $31.00) while maintaining a In Line rating.